"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 2 | 3 |
| 2001 | 3 | 0 | 3 |
| 2002 | 2 | 1 | 3 |
| 2003 | 5 | 3 | 8 |
| 2004 | 1 | 4 | 5 |
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 3 | 5 |
| 2007 | 1 | 2 | 3 |
| 2008 | 1 | 2 | 3 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 3 | 4 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 3 | 5 |
| 2016 | 3 | 3 | 6 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 5 | 3 | 8 |
| 2020 | 2 | 3 | 5 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leuk Lymphoma. 2023 05; 64(5):1026-1034.
-
IgA Nephropathy with Crescents: A Single-Center Experience. Am J Nephrol. 2022; 53(11-12):786-793.
-
Long term follow-up of Behçet's syndrome patients treated with cyclophosphamide. Rheumatology (Oxford). 2020 Sep 01; 59(9):2264-2271.
-
Should Pre-Transplant Hemoglobin A1c Be Used to Predict Post-Transplant Compliance in End-Stage Renal Disease Patients Undergoing Kidney Transplantation? Ann Transplant. 2020 Jun 26; 25:e924061.
-
T-cell large granular lymphocytic leukemia successfully treated with oral cyclosporine in a child: Case report and review of literature. Pediatr Blood Cancer. 2020 12; 67(12):e28487.
-
The rare case of a 20-year-old male with rapidly progressive primary angiitis of the CNS with a good outcome. Neurol Neuroimmunol Neuroinflamm. 2020 09; 7(5).
-
Calcineurin-inhibitor induced pain syndrome after stem cell transplant. Leuk Lymphoma. 2020 09; 61(9):2230-2233.
-
Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program. Ophthalmology. 2020 10; 127(10):1405-1415.
-
Chronic rhinosinusitis precipitated by tumor necrosis factor alpha inhibitors is the phenotype of chronic rhinosinusitis without nasal polyps. Int Forum Allergy Rhinol. 2020 01; 10(1):23-28.
-
Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study. Am J Transplant. 2020 01; 20(1):159-171.